维普期刊资源整合服务平台（V6.5）

38篇 您的检索式：作者名="BAILA L"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy:final results of the randomized phase Ⅲ study (06011) of the EORTC leukemia and German MDS study groups显示文摘	Wijermans P Suciu S Baila L	2008	Blood2008，112，：	1
2	Low dosedecitabine versus best supportive care in elderly pa-tients with intermediate or high-risk MDS not eligiblefor intensive chemotherapy:Final results of the ran-domized phaseⅢstudy(06011)of the EORTC leuke-mia and German MDS study groups显示文摘	WIJERMANS P SUCIU S BAILA L	2008	Blood2008，112，：	1
3	Low-dose decitabine versus best supportive care in elderly patients with intermediate or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase Ⅲ study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group显示文摘	Lubbert M Suciu S Baila L	2011	J Clin Oncol2011，29，15：	1
4	Low-dose decitabine ver- sus best supportive care in elderly patients with intermediate or high-risk myelodysplastic syndrome (MDS) ineligible for in- tensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treat- ment of Cancer Leukemia Group and the German MDS Study Group显示文摘	Ltibbert M Suciu S Baila L	2011	J Clin Oncol2011，29，15：	1
5	Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase IlI study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group显示文摘	LUBBERT M SUCIU S BAILA L	2011	J C/in Oncol2011，29，15：	1
6	Low-dose decitabine versus best supportive care in elderly pa- tients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemothera- py:final results of the randomized phase III study of the European Organisation for Research and Treat- ment of Cancer Leukemia Group and the German MDS Study Group显示文摘	LOBBERT M SUCIU S BAILA L	2011	J Clin Oncol2011，29，：	1
7	Low Dose Decitabine Versus Best Supportive Care in Eld III Study (0erly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results of the Randomized Phase6011) of the EORTC Leukemia and Ger- man MDS Study Groups显示文摘	WlJERMANS P SUCIU S BAILA L	2008	Blood (ASH Annual Meeting Abstracts)2008，112，：	1
8	Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome(MDS)ineligible for intensive chemotherapy:final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group显示文摘	LBBERT M SUCIU S BAILA L	2011	J Clin Oncol2011，29，：	1
9	Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-riskmyelodysplastic syndrome(MDS)ineligible for intensive chemotherapy:final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDSStudy Group显示文摘	Lübbert M Suciu S Baila L	2011	J Clin Oncol2011，29，15：	1
10	Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy:final results of the randomized phase m study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group 显示文摘	Ltibbert M Suciu S Baila L	2011	J Clin Oneo12011，29，15：	1
11	Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastie syndrome (MDS) ineligible for intensive ehemotherapy: final results of the randomized phase study of the european organisation for research and treatment of cancer leukemia group and the german MDS study group显示文摘	Liibbert M Suciu S Baila L el: al	2011	J Clin Oncol2011，29，15：	1
12	Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome(MDS) ineligible for intensive chemotherapy:final results of the randomized phase Ⅲ study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the GermanMDS Study Group显示文摘	Lübbert M Suciu S Baila L	2011	J Clin Oncol2011，29，15：	1
13	Low-dose decitabine versus best supportive care in elderly patients with intermediate or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy:final results of the randomized phase III study of the European Organisation for Resear显示文摘	Lubbert M Suciu S Baila L		0，，15：	1
14	Low-dose decitabine versus best supportive care in elderly patients with Inter- mediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase 11 study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group显示文摘	Ltibbert M Suciu S Baila L	2011	J Clin Oncol2011，29，15：	1
15	Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome(MDS) ineligible for inten- sive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group显示文摘	Lfibbert M Suciu S Baila L	2011	j Clin Oncol2011，29，15：	1
16	Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for inten- sive chemotherapy: final results of the randomized phase Illstudy of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group 显示文摘	Liibbert M Suciu S Baila L	2011	J Clin Oncol2011，29，15：	1
17	Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group 显示文摘	Lubbert M Suciu S Baila L	2011	J Clin Oncol2011，29，15：	1
18	Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy:final results of the randomized phase Ⅲ study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group显示文摘	Lubbert M Suciu S Baila L	2011	J Clin Oncol2011，29，：	1
19	Low- dose decitabine versus best supportive care in elderly patients with intermediate- or high- risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group显示文摘	Liibbert M Suciu S Baila L	2011	J Clin Oncol2011，29，15：	1
20	Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy:final results of the randomized phase Ⅲ study of the European Organisation for Research显示文摘	Lubbert M Suciu S Baila L		0，，15：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示